Table 1

Net effect of donation on survival and ESRD in current donors assuming average future population risks

OutcomeWhite maleWhite femaleBlack maleBlack female
Remaining life years, non-donor39.578 years
(39.513 to 39.819)*
43.992 years
(43.872 to 44.46)
35.945 years
(35.768 to 36.112)
41.551 years
(41.249 to 41.803)
Lost life years (%) postdonation−0.767 (1.94%)
(−0.702 to –1.008)
−0.532 (1.2%)
(−0.412 to –0.804)
−0.841 (2.34%)
(−0.664 to –1.008)
−0.884 (2.13%)
(−0.582 to –1.136)
Remaining QALYs, non-donor21.871 QALYs
(21.849 to 21.951)
23.256 QALYs
(23.218 to 23.338)
20.419 QALYs
(20.358 to 20.476)
22.151 QALYs
(22.058 to 22.223)
Lost QALYs (%) postdonation−0.272 (1.24%)
(−0.250 to –0.352)
−0.177 (0.76%)
(−0.139 to –0.259)
−0.308 (1.51%)
(−0.247 to –0.365)
−0.283 (1.28%)
(−0.190 to –0.355)
Cumulative lifetime ESRD, non-donor %1.118%
(0.568 to 1.397)
0.535%
(0.254 to 0.713)
1.257%
(0.731 to 1.974)
1.157%
(0.621 to 2.106)
Added cumulative ESRD % postdonation+3.858% (1/26)
(1/23 to 1/28)
+1.135% (1/88)
(1/71 to 1/100)
+4.645% (1/22)
(1/19 to 1/25)
+3.741% (1/27)
(1/23 to 1/36)
Loss from ESRD
 Life years (%)−0.292 (0.74%)−0.126 (0.29%)−0.344 (0.88%)−0.297 (0.71%)
 QALYs (%)−0.094 (0.43%)−0.039 (0.17%)−0.128 (0.62%)−0.090 (0.41%)
  • *Values in parentheses represent the impact of higher and lower cumulative risks of ESRD taken from the upper and lower bounds of the 95% CIs for 15-year cumulative risk of ESRD (online supplementary ref 11).

  • ESRD, end-stage renal disease; QALYs, quality-adjusted life years.